MedTrace Logo

DNS-7801 vs. Placebo in Parkinson's Disease

NCT03306329 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-02-01

No results posted yet for this study

Summary

This is a randomized, double-blind, two-part placebo-controlled parallel group outpatient treatment study that will utilize standard Parkinson's Disease measures to evaluate the effect of DNS-7801

Conditions

Interventions

DRUG

DNS-7801 (low-dose)

DNS-7801 (low-dose) tablets administered once daily.

DRUG

DNS-7801 (high dose)

DNS-7801 (high dose) tablets administered once daily.

DRUG

Placebo

Placebo tablets administered once daily

Sponsors & Collaborators

  • Dart NeuroScience, LLC

    lead INDUSTRY

Principal Investigators

  • Philip Perera, MD · Dart NeuroScience, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2017-12-31
Completion
2017-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03306329 on ClinicalTrials.gov